These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 24158229)

  • 41. Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs.
    Campese VM
    Clin Exp Nephrol; 2014 Apr; 18(2):291-5. PubMed ID: 24535025
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical implications of statin therapy in patients undergoing hemodialysis.
    Kim JJ; Langworthy DR; Hennessey EK
    Am J Health Syst Pharm; 2014 May; 71(9):703-10. PubMed ID: 24733132
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dyslipidemia, malnutrition, inflammation, cardiovascular disease and mortality in chronic kidney disease.
    Peev V; Nayer A; Contreras G
    Curr Opin Lipidol; 2014 Feb; 25(1):54-60. PubMed ID: 24345987
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiovascular disease in patients with renal disease: the role of statins.
    Fellström B; Holdaas H; Jardine AG; Svensson MK; Gottlow M; Schmieder RE; Zannad F;
    Curr Med Res Opin; 2009 Jan; 25(1):271-85. PubMed ID: 19210158
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Chou R; Dana T; Blazina I; Daeges M; Jeanne TL
    JAMA; 2016 Nov; 316(19):2008-2024. PubMed ID: 27838722
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of statins in preventing adverse cardiovascular outcomes in patients with chronic kidney disease.
    Navaneethan SD; Hegbrant J; Strippoli GF
    Curr Opin Nephrol Hypertens; 2011 Mar; 20(2):146-52. PubMed ID: 21245764
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dyslipidemia in chronic kidney disease: are statins still indicated in reduction cardiovascular risk in patients on dialysis treatment?
    Scarpioni R; Ricardi M; Melfa L; Cristinelli L
    Cardiovasc Ther; 2010 Dec; 28(6):361-8. PubMed ID: 20553296
    [TBL] [Abstract][Full Text] [Related]  

  • 48. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Meta-analysis of statin therapy in maintenance dialysis patients.
    Sun L; Zou L; Chen M; Liu B
    Ren Fail; 2015 Aug; 37(7):1149-56. PubMed ID: 26139229
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Kidney and lipids: novel potential therapeutic targets for dyslipidemia in kidney disease?
    Zuzda K; Grycuk W; Małyszko J; Małyszko J
    Expert Opin Ther Targets; 2022 Nov; 26(11):995-1009. PubMed ID: 36548906
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dyslipidemia in children with CKD: should we treat with statins?
    Tullus K
    Pediatr Nephrol; 2012 Mar; 27(3):357-62. PubMed ID: 21487766
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Statin use in patients with diabetes and kidney disease: the Japanese experience.
    Koya D; Campese VM
    J Atheroscler Thromb; 2013; 20(5):407-24. PubMed ID: 23518468
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of statins on renal function in patients with chronic kidney disease: a systematic review and meta-analysis.
    Zhao L; Li S; Gao Y
    Ren Fail; 2021 Dec; 43(1):718-728. PubMed ID: 33926359
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Clinical practice guidelines for the management of dyslipidemia in chronic kidney disease].
    Shoji T
    Nihon Jinzo Gakkai Shi; 2013; 55(7):1267-75. PubMed ID: 24288962
    [No Abstract]   [Full Text] [Related]  

  • 55. Statins and Cardiovascular Primary Prevention in CKD: A Meta-Analysis.
    Major RW; Cheung CK; Gray LJ; Brunskill NJ
    Clin J Am Soc Nephrol; 2015 May; 10(5):732-9. PubMed ID: 25833405
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dyslipidemia, statins, and CKD patients' outcomes - review of the evidence in the post-sharp era.
    Heymann EP; Kassimatis TI; Goldsmith DJ
    J Nephrol; 2012; 25(4):460-72. PubMed ID: 22641572
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Statins and Cardiovascular Disease Outcomes in Chronic Kidney Disease: Reaffirmation vs. Repudiation.
    Obialo CI; Ofili EO; Norris KC
    Int J Environ Res Public Health; 2018 Dec; 15(12):. PubMed ID: 30518032
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cardiovascular disease: Should statin therapy be expanded in patients with CKD?
    Jablonski KL; Chonchol M
    Nat Rev Nephrol; 2012 Jul; 8(8):440-1. PubMed ID: 22751508
    [No Abstract]   [Full Text] [Related]  

  • 59. Statins and renal disease: friend or foe?
    Deshmukh A; Mehta JL
    Curr Atheroscler Rep; 2011 Feb; 13(1):57-63. PubMed ID: 21053107
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
    Navaneethan SD; Pansini F; Perkovic V; Manno C; Pellegrini F; Johnson DW; Craig JC; Strippoli GF
    Cochrane Database Syst Rev; 2009 Apr; (2):CD007784. PubMed ID: 19370693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.